INTRODUCTION {#s1}
============

Adrenocorticotropic hormone (ACTH) was one of the first therapies widely used several decades ago for the treatment of childhood nephrotic syndrome \[[@SFW045C1]\]. It fell out of favor after easy-to-use synthetic oral glucocorticoids became available \[[@SFW045C2]\]. Recently, ACTH has been resurrected as a potential therapeutic option for a variety of glomerular diseases \[[@SFW045C3]--[@SFW045C7]\]. In addition to its steroidogenesis effects, ACTH acts as an agonist of the melanocortin system, which plays a role in various physiologic functions, including melanin synthesis, immunomodulation, anti-inflammation, lipolysis stimulation and modulation of exocrine function \[[@SFW045C8]\]. Animal studies have suggested that the antiproteinuric effect of ACTH might in fact be mediated through the melanocortin receptors that are expressed on glomerular podocytes and renal parenchymal cells \[[@SFW045C9], [@SFW045C10]\]. This was shown in the rat model of passive Heymann nephritis \[[@SFW045C10]\]. The rats that were treated with specific melanocortin 1 receptor agonist had a significantly lower degree of proteinuria compared with the untreated rats. Studies in humans have also shown ACTH to be effective in reducing proteinuria in patients with nephrotic syndrome who have not responded to corticosteroid treatment, thereby suggesting that noncorticosteroid mechanisms may play a role \[[@SFW045C3]--[@SFW045C6]\].

Since the therapeutic effect of ACTH on nephrotic syndrome was first reexamined by Berg *et al*. \[[@SFW045C3]\] in 1999, the literature on its use in various glomerular diseases has rapidly expanded \[[@SFW045C4]--[@SFW045C7], [@SFW045C11]--[@SFW045C13]\]. However, the exact efficacy of ACTH in inducing remission in patients with glomerular diseases and the frequency of adverse effects associated with the use of ACTH remain largely unknown. Given the absence of data, we undertook this systematic review and meta-analysis to evaluate the efficacy and establish the incidence of adverse effects associated with ACTH in treating various types of glomerular diseases.

METHODS {#s2}
=======

This systematic review and meta-analysis is reported in accordance with previously published guidelines \[[@SFW045C14], [@SFW045C15]\].

Search strategy {#s2a}
---------------

Published studies in the Cochrane Database of Systematic Reviews, Embase, Medline and Google Scholar were evaluated by two investigators (W.K. and W.C.) from inception through 18 July 2015 as outlined in [Item S1 in Supplementary data](http://ckj.oxfordjournals.org/lookup/suppl/doi:10.1093/ckj/sfw045/-/DC1). Additional pertinent studies were obtained by performing a manual search using references from the articles that were retrieved from the search strategy noted above.

Selection criteria {#s2b}
------------------

The inclusion criteria were as follows: (i) the studies were randomized controlled trials (RCTs) or observational studies (case--control, cross-sectional, cohort studies or case series), (ii) data on either efficacy or safety of ACTH treatment in glomerular diseases were provided and (iii) the primary study patients had reached adulthood (age \>18 years old). The search was limited to English-language articles. Both published articles and conference abstracts were included. Study eligibility was independently determined by the two investigators noted above. Differing decisions were resolved by mutual consensus.

Data extraction {#s2c}
---------------

A standardized data collection form was used to extract the following information: last name of the first author, study design, publication year, country where the study was conducted, number of patients studied, characteristics of included participants, period of follow-up, type of glomerular disease, form of ACTH preparation, dosing, duration of treatment, treatment response and type and number of adverse effects following ACTH treatment.

Statistical analysis {#s2d}
--------------------

MetaXL software (EpiGear International, Sunrise Beach, QLD, Australia) \[[@SFW045C16]\] was used for data analysis. The incidence rates (IRs) and 95% confidence intervals (CIs) of adverse effects were reported using a DerSimonian--Laird random-effects model \[[@SFW045C17]\]. A random-effects model was used for data analysis due to the high likelihood of interstudy variances and the Cochran Q test was performed to assess statistical heterogeneity. The *I*^2^ statistic was added to evaluate the degree of variation across studies related to heterogeneity instead of chance. 'An *I*^2^ of 0--25% represents insignificant heterogeneity, 26--50% low heterogeneity, 51--75% moderate heterogeneity and \>75% high heterogeneity' \[[@SFW045C18]\]. The frequencies of each type of adverse effect were presented as a crude percentage. To assess for publication bias funnel plots were used.

RESULTS {#s3}
=======

A flow diagram for retrieval and inclusion of studies is shown in Figure[ 1](#SFW045F1){ref-type="fig"}. Our search strategy yielded 343 potentially relevant articles. Three hundred and one articles were excluded after the initial screening and 42 articles were included for full-length review. Eventually, 19 articles met all the inclusion criteria \[[@SFW045C3]--[@SFW045C7], [@SFW045C11]--[@SFW045C13], [@SFW045C19]--[@SFW045C29]\]. Details of these studies are outlined in Table [1](#SFW045TB1){ref-type="table"}. Table 1.Main characteristics of the included studiesAuthorType of publicationStudy design*n*MNFSGSMCDIgADNLNMPGNOthersKhastgir *et al*. \[[@SFW045C25]\]Conference abstractRetrospective cohort9----25--2----Lorusso *et al*. \[[@SFW045C7]\]ArticleProspective cohort181023------3--Hladunewich *et al*. \[[@SFW045C13]\]ArticleProspective cohort2020--------------Finocchietti *et al*. \[[@SFW045C12]\]Conference abstractProspective cohort1919--------------Madan *et al*. \[[@SFW045C24]\]Conference abstractRetrospective cohort224725211--Tumlin *et al.* \[[@SFW045C23]\]ArticleProspective cohort14--------14------Hogan *et al*. \[[@SFW045C6]\]ArticleRetrospective cohort24--24------------Berg *et al*. \[[@SFW045C22]\]Conference abstractRetrospective cohort10--10------------Berg and Back (2013) \[[@SFW045C21]\]Conference abstractRetrospective cohort5----------5----Bomback *et al*. \[[@SFW045C5]\]ArticleProspective cohort1553\*25----Bomback *et al*. \[[@SFW045C4]\]ArticleRetrospective cohort21111\*11--142Hofstra *et al*. \[[@SFW045C20]\]Conference abstractProspective cohort1414--------------Rauen *et al*. \[[@SFW045C19]\]ArticleRetrospective cohort44--------------Ponticelli *et al*. \[[@SFW045C11]\]ArticleRandomized controlled trial1616--------------Berg *et al*. \[[@SFW045C29]\]Conference abstractRandomized controlled trial1515--------------Picardi *et al*. \[[@SFW045C28]\]Letter to the editorRetrospective cohort77--------------Berg and Arnadottir \[[@SFW045C27]\]ArticleRetrospective cohort231012--2----8Berg *et al*. \[[@SFW045C3]\]ArticleProspective cohort1414--------------Berg and Nilsson-Ehle \[[@SFW045C26]\]ArticleProspective cohort9------1--1--7Total2791494812171810817[^1][^2] Fig. 1.Study selection flow chart.

Efficacy of ACTH in the treatment of glomerular diseases {#s3a}
--------------------------------------------------------

Eighteen studies \[[@SFW045C3]--[@SFW045C7], [@SFW045C11]--[@SFW045C13], [@SFW045C19]--[@SFW045C25], [@SFW045C27]--[@SFW045C29]\] were included for the evaluation of drug efficacy (*n* = 270), consisting of 10 published articles, 1 letter to the editor and 7 conference abstracts. There were two RCTs, seven prospective cohorts and nine retrospective cohorts. These studies included participants with membranous nephropathy (MN; *n*= 149), focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD; *n* = 60), IgA nephropathy (*n* = 16), lupus nephritis (*n* = 9), diabetic nephropathy (*n* = 18) and other glomerular diseases (*n* = 18).

The included studies were heterogeneous in regard to patient characteristics, disease severity, the form of ACTH preparations, ACTH dosing, treatment duration, follow-up duration and response criteria. Therefore, the treatment responses were reevaluated based on the information provided on individual patients using the same response criteria. Complete remission was defined as a final urinary protein excretion ≤0.3 g/day. Partial remission was defined as a ≥50% reduction in urinary protein excretion and urinary protein excretion \<3.5 g/day. All patients failing to meet these criteria were deemed as nonresponders. However, response reevaluation is not applicable to the abstracts due to the limited data available on each individual patient.

Membranous nephropathy {#s3b}
----------------------

A total of nine published studies \[[@SFW045C3]--[@SFW045C5], [@SFW045C7], [@SFW045C11], [@SFW045C13], [@SFW045C19], [@SFW045C27], [@SFW045C28]\] with 97 MN patients and four abstracts \[[@SFW045C12], [@SFW045C20], [@SFW045C24], [@SFW045C29]\] with 52 MN patients were included. We grouped patients based on the duration of follow-up, with a summary of baseline characteristics and response rates as presented in Tables [2](#SFW045TB2){ref-type="table"} and [3](#SFW045TB3){ref-type="table"}. One hundred and nine patients from nine studies \[[@SFW045C3], [@SFW045C7], [@SFW045C11], [@SFW045C12], [@SFW045C19], [@SFW045C20], [@SFW045C27]--[@SFW045C29]\] were treated with synthetic ACTH (tetracosactide), whereas 40 patients from four studies \[[@SFW045C4], [@SFW045C5], [@SFW045C13], [@SFW045C24]\] were treated with natural ACTH (H.P. Acthar gel; Mallinckrodt). The dose of synthetic ACTH ranged from 0.25 to 2 mg/week and natural ACTH was 80--160 units/week. The duration of treatment ranged from 2 to 24 months and maximum follow-up duration was 82 months. The overall response rate (complete and partial remission) for MN was 80% at 0--6 months, 69% at 6--12 months, 90% at 12--24 months and 95% in those with \>24 months of follow-up (Table [2](#SFW045TB2){ref-type="table"}). There were four relapses reported after discontinuation of ACTH (3%). Table 2.Summary of published articles on adrenocorticotropic hormone therapy in membranous nephropathyAuthorNumber of patientsImmunosuppression response categoryACTH preparationTotal dose (per week)Duration of treatment (months)Baseline proteinuria (g or g/g)Baseline GFR (mL/min/1.73 m^2^)Baseline Cr (mg/dL)Baseline serum albumin (g/dL)CRPRNRRelapseFollow-up duration 0--6 months Bomback *et al*. \[[@SFW045C5]\]55 IRNatural160 U63.8 (2.2--12.5)34 (21--44)2 (1.6--2.9)NA0230 Bomback *et al*. \[[@SFW045C4]\]55 IRNatural120--160 U66.7 (4.6--9)57 (21 to \>60)NANA0500 Ponticelli *et al*. \[[@SFW045C11]\]1616 naïveSynthetic2 mg66 (4.4--8.5)^a^NA1 (3.6)^b^NA3850 Berg *et al*. \[[@SFW045C3]\]144 IR/7 SR/3 naïveSynthetic1.6 mg24.8 (3.7--15.9)43 (20--78)1.5 (1.1--3.6)2.3 (1.2--3.2)11300 Total patients404 (10%)28 (70%)8 (20%)0 (0%)Follow-up duration \>6--12 months Lorusso *et al*. \[[@SFW045C7]\]9NASynthetic1 mg124 (3--10)NANA3.2 (2.2--4.1)4050 Hladunewich *et al*. \[[@SFW045C13]\]20Excluded IR or SRNatural80--160 U39 (3.4)^b^77 (30)^b^NA2.7 (0.8)^b^21080 Bomback *et al*. \[[@SFW045C4]\]43 IR/1 naïveNatural120--160 U6 (5--11)9 (4.9--11.9)42.5 (20 to \>60)NANA1120 Ponticelli *et al*. \[[@SFW045C11]\]1616 naïveSynthetic2 mg126 (4.4--8.5)^a^NA1 (3.6)^b^NA10420 Berg *et al*. \[[@SFW045C27]\]1NASynthetic0.5--2 mg77.8NANANA1000 Berg *et al*. \[[@SFW045C3]\]54 IR/1 SRSynthetic2 mg128.8 (7.1--13.7)45 (20--61)1.5 (1.1--3.6)1.7 (1.2--1.9)4100 Total patients5522 (40%)16 (29%)17 (31%)0 (0%)Follow-up duration \>12--24 months Lorusso *et al*. \[[@SFW045C7]\]2NASynthetic1 mg126.6 (3.2--10)NANA2.4 (2.2--2.6)0021 Bomback *et al*. \[[@SFW045C4]\]22 IRNatural80--160 U123 (2.5--3.6)60 (40 to \>60)NANA2000 Ponticelli *et al*. \[[@SFW045C11]\]99 naïveSynthetic2 mg12NANANANA6300 Berg *et al*. \[[@SFW045C27]\]2NASynthetic0.5--2 mg9 (7--11)5.4 (3.5--7.3)NANANA1100 Berg *et al*. \[[@SFW045C3]\]54 IR/1 SRSynthetic2 mg128.8 (7.1--13.7)45 (20--61)1.5 (1.1--3.6)1.7 (1.2--1.9)4100 Total patients2013 (65%)5 (25%)2 (10%)1 (5%)Follow-up duration \>24 months Lorusso *et al*. \[[@SFW045C7]\]5NASynthetic1 mg124 (3--8.6)NANA3.7 (2.6--4.1)2210 Rauen *et al*. \[[@SFW045C19]\]44 IR^c^Synthetic0.25--2.25 mg13 (3--24)9.6 (6--20)39.5 (20--62)NANA2200 Berg *et al*. \[[@SFW045C27]\]7NASynthetic0.5--2 mg2--117.5 (3.2--26.7)NA1.2 (0.7--5.4)1.9 (1--2.3)3401 Berg *et al*. \[[@SFW045C3]\]54 IR/1 SRSynthetic2 mg128.8 (7.1--13.7)45 (20--61)1.5 (1.1--3.6)1.7 (1.2--1.9)4100 Total patients2111 (52%)9 (43%)1 (5%)1 (5%)[^3][^4][^5][^6][^7] Table 3.Summary of conference abstracts and letters to the editor on adrenocorticotropic hormone therapy in membranous nephropathyAuthorNumber of patientsImmunosuppression response categoryACTH preparationTotal dose (per week)Duration of treatment (months)Follow-up duration (months)CRPRNREarly terminationFinocchietti *et al*. \[[@SFW045C12]\]^a,b^19NASynthetic1 mg1212NANANA0Madan *et al*. \[[@SFW045C24]\]^c^43 SR or IR, 1 naïveNatural160 U\>6NA1111Hofstra *et al*. \[[@SFW045C20]\]^a^14NASyntheticMax 2 mg910--210482Berg *et al*. \[[@SFW045C29]\]^d^1515 naïveSynthetic1--2 mg92111310Picardi *et al*. \[[@SFW045C28]\]7NASynthetic2 mg12125002[^8][^9][^10][^11][^12]

Of the 13 published studies and abstracts, only 2 were RCTs comparing ACTH injections with other therapies in MN. One was presented as an abstract comparing ACTH plus an angiotensin-converting enzyme inhibitor to an angiotensin-converting enzyme inhibitor only \[[@SFW045C29]\]. Thirty patients with MN were randomized into each arm. ACTH induced remission in all 15 patients who received synthetic ACTH for 9 months, compared with 1 of 15 patients in the control group. The other RCT compared the efficacy of 6 months of methylprednisolone alternating with alkylating agents to 1 year of synthetic ACTH 1 mg twice weekly \[[@SFW045C11]\]. There were no significant differences between the two treatment groups in terms of the number of remissions at 12 months (93 versus 87%), median time to response (2 versus 3 months), number of relapse (7 versus 3 patients) or the decrease in the degree of proteinuria (5.1--2.1 g/day versus 6.0--0.3 g/day). However, in patients treated with ACTH, time spent without nephrotic syndrome was longer and more complete remissions were achieved.

Only one study, by Hladunewich *et al*. \[[@SFW045C13]\], compared the efficacy of different doses of natural ACTH (H.P. Acthar gel) in 20 patients with MN. Nine patients were randomly assigned to receive ACTH 40 units twice weekly and 11 were assigned to receive 80 units twice weekly. At the end of a 12-week treatment period, none of the patients in the 40-unit arm achieved a meaningful change in proteinuria, whereas 5 of 11 patients in the 80-unit arm had at least a 30% reduction in proteinuria. The authors suggested that the cumulative dose of natural ACTH (80 units twice weekly) for at least 3 months appeared to be necessary for a response. No studies have directly compared the efficacy of different doses of synthetic ACTH when treating patients. The majority of the synthetic ACTH studies have used 2-mg weekly dose, but a case series using low-dose synthetic ACTH (1 mg weekly) also reported a reasonable response rate (44% at 12 months) \[[@SFW045C7]\]. The equivalent dosage of natural versus synthetic ACTH is not known.

Of the nine published studies that included patients with MN, only four studies included patients (*n* = 29) who had previously failed other immunosuppressive therapy such as cyclophosphamide, mycophenolate mofetil, calcineurin inhibitor, rituximab or corticosteroids \[[@SFW045C3]--[@SFW045C5], [@SFW045C19]\]. Twenty-five of the 29 (86%) achieved remission after 6 months of follow-up.

FSGS and MCD {#s3c}
------------

There were five published studies (*n* = 35) \[[@SFW045C4]--[@SFW045C7], [@SFW045C27]\] and three abstracts (*n* = 21) \[[@SFW045C22], [@SFW045C24], [@SFW045C25]\] that included patients with FSGS or MCD (excluding 4 FSGS patients from Bomback *et al*. \[[@SFW045C4], [@SFW045C5]\] who were included in the study by Hogan *et al*. \[[@SFW045C6]\]) (Tables [4](#SFW045TB4){ref-type="table"} and [5](#SFW045TB5){ref-type="table"}). Treatment duration ranged from 2 to 56 months. Of the 56 patients with FSGS or MCD, 38 (68%) were treated with natural ACTH \[[@SFW045C4]--[@SFW045C6], [@SFW045C24], [@SFW045C25]\] and 18 (32%) were treated with synthetic ACTH \[[@SFW045C7], [@SFW045C21], [@SFW045C27]\]. Of the 35 patients (from the published articles), 27 had failed previous immunosuppressive therapy including steroids \[[@SFW045C4]--[@SFW045C7], [@SFW045C27]\]. The overall response rate was 50% after 6 months of follow-up. Six of 35 patients (17%) experienced relapse after ACTH discontinuation. According to the largest study with 24 FSGS patients by Hogan *et al*. \[[@SFW045C6]\], patients who experienced remission were either steroid resistant or dependent. The remitters tended to have a lower serum creatinine at baseline. However, no associations were observed between age, ethnicity, FSGS subtype, use of additional immunosuppression during ACTH treatment, accumulative dose or duration of ACTH therapy and the rate of remission. Table 4.Summary of published articles on adrenocorticotropic hormone therapy in focal segmental glomerulosclerosis and minimal change diseaseAuthorNumber of patientsImmunosuppression response categoryACTH preparationTotal dose (per week)Duration of treatment (month)Baseline proteinuria (g or g/g)Baseline GFR (mL/min/1.73 m^2^)Baseline Cr (mg/dL)Baseline serum albumin (g/dL)CRPRNRRelapseFollow-up duration 6--12 months Bomback *et al*. \[[@SFW045C5]\]22 IRNatural160 U64 (3.2--4.8)120 (117--123)0.65 (0.6--0.7)3 (2.5--3.4)0111 Bomback *et al*. \[[@SFW045C4]\]11 IRNatural160 U418.615NANA0010 Berg *et al*. \[[@SFW045C27]\]11 SRSynthetic0.5--2 mg79.6NANANA0100 Total patients40 (0%)2 (50%)2 (50%)1 (25%)Follow-up duration \>12--24 months Lorusso *et al*. \[[@SFW045C7]\]^a^4NASynthetic1 mg127.7 (3--13)NANA2.9 (1.7--3.4)2112 Hogan *et al*. \[[@SFW045C6]\]^b^1715 SR or SD, 2 naïveNatural160 U16 (12--24)4.6 (1.6--23.8)47 (23--124)1.5 (0.6--3.3)3.2 (1.6--4.8)23122 Berg *et al*. \[[@SFW045C27]\]11 SRSynthetic0.5--2 mg23.9NANANA1001 Total patients225 (23%)4 (18%)13 (59%)5 (23%)Follow-up duration \>24 months Lorusso *et al*. \[[@SFW045C7]\]1NASynthetic1 mg123NANA2.40100 Hogan *et al*. \[[@SFW045C6]\]66 SD or SRNatural160 U36 (28--56)9.6 (2.3--15.2)29 (17--67)2.5 (1.1--3.6)2.1 (1.3--2.9)0240 Berg *et al*. \[[@SFW045C27]\]11 SRSynthetic0.5--2 mg73.4NANANA0100 Total patients80 (0%)4 (50%)4 (50%)0 (0%)[^13][^14][^15][^16] Table 5.Summary of abstracts on adrenocorticotropic hormone therapy in focal segmental glomerulosclerosis and minimal change diseaseAuthorNumber of patientsImmunosuppression response categoryACTH preparationTotal dose (per week)Duration of treatment (months)Follow-up duration (months)CRPRNREarly terminationKhastgir *et al*. \[[@SFW045C25]\]^a^22 IRNatural160 U\>6\>62000Madan *et al*. \[[@SFW045C24]\]^b^8NANatural160 U\>6\>62331Berg *et al*. \[[@SFW045C22]\]^c,d^10NASynthetic2 mg18 (7--48)0--29^e^3520[^17][^18][^19][^20][^21][^22]

Other glomerular diseases {#s3d}
-------------------------

The evidence for ACTH treatment in other glomerular diseases is summarized in [Supplementary data, Table S1](http://ckj.oxfordjournals.org/lookup/suppl/doi:10.1093/ckj/sfw045/-/DC1). Most studies were small and heterogeneous and therefore it was difficult to draw any conclusions on the effectiveness of ACTH therapy.

Adverse effects {#s3e}
---------------

There were 12 studies that reported adverse effects associated with ACTH in a total of 171 patients with underlying glomerular diseases including MN (*n* = 87), FSGS (*n* = 30), MCD (*n* = 8), IgA nephropathy (*n* = 12), lupus nephritis (*n* = 4), diabetic nephropathy (*n* = 14) and other (*n* = 16) \[[@SFW045C3]--[@SFW045C7], [@SFW045C11], [@SFW045C13], [@SFW045C19], [@SFW045C23], [@SFW045C25], [@SFW045C26], [@SFW045C28]\]. The dose of synthetic ACTH ranged from 0.25 to 3.3 mg/week and natural ACTH was 80 to 224 units/week. Treatment duration ranged from 2 to 48 months. Table [6](#SFW045TB6){ref-type="table"} summarizes the major adverse effects of ACTH. [Supplementary data, Figure S1](http://ckj.oxfordjournals.org/lookup/suppl/doi:10.1093/ckj/sfw045/-/DC1) shows the forest plot of the included studies. Edema was the most common adverse effect (IR 0.10), followed by insomnia (IR 0.08), hyperglycemia (IR 0.07) and mood swings (IR 0.07). The dropout rate due to adverse events was 7%, mostly due to edema and weight gain (5 of 12 patients). No severe adverse reactions or deaths associated with ACTH injections were reported (Table [7](#SFW045TB7){ref-type="table"}). The adverse effect profiles of natural and synthetic ACTH were similar (Table [6](#SFW045TB6){ref-type="table"}). Table 6.Adverse effects of ACTHAdverse effectsAllNatural ACTHSynthetic ACTHIncidence rate95% CI*I*^2^P-valueIncidence rate95% CI*I*^2^P-valueIncidence rate95% CI*I*^2^P-valueEdema0.100.04--0.18520.020.090.01--0.21660.010.100.02--0.22400.14Insomnia/increased alertness0.080.03--0.15530.020.120.03--0.25650.010.030.00--0.0900.58Mood swings0.070.02--0.14570.010.060.00--0.17690.010.070.00--0.18460.10Hyperglycemia0.070.04--0.1100.520.100.05--0.1600.520.040.00--0.0900.59Hyperpigmentation0.060.02--0.12440.050.060.02--0.12120.340.060.00--0.18640.02Hypertension0.060.02--0.11360.110.050.01--0.11250.240.060.00--0.17510.07Weight gain0.060.03--0.11260.190.100.04--0.18260.240.030.00--0.0700.64Gastrointestinal symptoms0.060.01--0.12550.010.060.00--0.1973\<0.0010.040.01--0.1100.42Pain0.050.01--0.1367\<0.0010.090.00--0.2482\<0.0010.030.00--0.0800.95Dizziness0.040.01--0.08110.340.040.00--0.12520.060.030.00--0.0800.92Upper respiratory tract symptoms0.040.01--0.08280.170.030.00--0.09340.180.050.00--0.13310.20Fatigue0.040.01--0.1160\<0.0010.060.00--0.1978\<0.0010.030.00--0.0700.74Muscle cramps0.040.01--0.08280.170.030.00--0.09340.180.050.00--0.13310.20Flushing0.030.01--0.0600.830.040.01--0.0990.36Cushingoid appearance0.030.01--0.0600.740.040.00--0.09250.24Rash0.030.01--0.0600.860.020.00--0.0600.690.040.00--0.1000.72Respiratory tract infection0.020.01--0.0500.990.020.00--0.0500.940.030.00--0.0800.89Bone loss0.020.00--0.040\>0.990.020.00--0.0500.92Tremor0.020.01--0.0500.830.030.00--0.07180.30Hoarseness0.020.00--0.0500.970.020.00--0.0600.60Acne0.020.00--0.050\>0.990.040.01--0.0900.47Blurred vision0.020.00--0.0500.970.020.00--0.0600.60Polyuria0.020.01--0.050\>0.990.020.00--0.0500.940.030.00--0.0800.95Palpitations0.020.01--0.050\>0.990.020.00--0.0500.940.030.00--0.0800.95Increased appetite0.020.00--0.050\>0.990.020.00--0.0500.94Delayed wound healing0.020.00--0.050\>0.990.020.00--0.0500.94[^23] Table 7.Potential future considerations of ACTH in glomerular diseasesGlomerular diseaseIndicationTreatment regimenMNAs first-line therapy or in resistant MNACTH alone or in a combination with other immunosuppressive therapies. Response may depend on cumulative dose of ACTH \[[@SFW045C13]\]Suggested dose: -- Natural ACTH 80 IU twice weekly for at least 3 months \[[@SFW045C13]\]-- Synthetic ACTH (tetracosactide or Synacthen depot) 1 mg twice weekly for at least 3 months \[[@SFW045C11]\]FSGS and MCDResistant FSGS or MCD (data are limited)ACTH alone or in a combination with another immunosuppressive therapy Suggested dose: -- Natural ACTH (Acthar) 80 IU twice weekly for at least 6 months \[[@SFW045C5], [@SFW045C6]\]-- Synthetic ACTH (tetracosactide or Synacthen depot) 0.5--1 mg twice weekly for at least 6 months \[[@SFW045C7], [@SFW045C27]\]IgA nephropathyProteinuria \>1 g/day despite maximally tolerated RAAS blockade (data are limited)Suggested dose: -- Natural ACTH (Acthar) 80 IU twice weekly for at least 6 months \[[@SFW045C5]\][^24][^25]

Evaluation for publication bias {#s3f}
-------------------------------

Funnel plots to evaluate publication bias regarding the incidence of adverse effects of ACTH treatment in glomerular diseases are summarized in [Supplementary data, Figure S2](http://ckj.oxfordjournals.org/lookup/suppl/doi:10.1093/ckj/sfw045/-/DC1). The graphs for assessing publication bias are slightly asymmetric and suggest the presence of publication in favor of negative studies evaluating the incidence of acne, blurred vision, bone loss, muscle cramps, delayed wound healing, hoarseness, gastrointestinal tract symptoms, respiratory tract infection, polyuria and rash. The slight asymmetry of the graphs also suggests the presence of publication in favor of positive studies regarding the incidence of hyperpigmentation, cushingoid appearance, dizziness, fatigue, flushing, hypertension, insomnia, mood swings, pain, tremor, upper respiratory tract symptoms and weight gain. Otherwise, the graphs for assessing publication bias are insignificant in the selected studies for incidence of edema, hyperglycemia, increased appetite and palpitation.

DISCUSSION {#s4}
==========

In this study, we present the first systematic review of ACTH effectiveness and meta-analysis of its adverse effects in glomerular diseases. According to the current evidence, ACTH seems to be a promising treatment for nephrotic syndrome, especially MN. ACTH was shown to reduce proteinuria in patients with MN who previously failed to respond to oral corticosteroids, suggesting ACTH may have antiproteinuric effects besides its steroidogenic properties. However, the precise dose and duration of therapy required to produce a sustained response remain unknown. A study by Berg *et al*. \[[@SFW045C3]\] showed that a quick relapse of proteinuria and dyslipidemia occurred after 2 months of therapy with ACTH, whereas remission was sustained up to 30 months in a subgroup of patients who received ACTH for 12 months \[[@SFW045C3]\]. Hladunewich *et al*. \[[@SFW045C13]\] also pointed out that the degree of proteinuria was inversely related to the cumulative dose of ACTH. These data suggest that a higher cumulative dose of ACTH may be associated with more complete and sustained remission. ACTH was shown to reduce or completely clear antiphospholipase A2 receptor (PLA2R) in most patients who had a positive anti-PLA2R at baseline, suggesting that ACTH therapy may also exert therapeutic value by suppressing autoantibody production \[[@SFW045C5], [@SFW045C13]\].

In patients with FSGS and MCD, the treatment failure rate beyond 6 months of follow-up was high (∼50%) compared with patients with MN (5--31%). Reported relapses were also frequent after stopping treatment (17%). However, this may be due to the resistant nature of patients\' disease since the majority of included patients had failed to respond to two to three immunosuppressive agents in the past. Berg *et al*. \[[@SFW045C22]\] reported that 10 patients with FSGS had a reduction in proteinuria (5--1 g) after replacing oral corticosteroids with synthetic ACTH while continuing a second immunosuppressive agent. These data suggest that ACTH may have a potential role in treating patients with resistant FSGS or MCD. However, due to the small and heterogeneous nature of these studies, the evidence for efficacy of ACTH in FSGS and MCD is limited at the present time.

There are currently two forms of ACTH injections commercially available. One is natural ACTH (H.P. Acthar gel; Mallinckrodt), a 39-amino-acid peptide isolated from highly purified porcine pituitary extract, which is currently the only ACTH-containing product approved by the US Food and Drug Administration for treatment of patients with nephrotic syndrome in the USA. The second is a synthetic form of ACTH, containing only the first 24 amino acids from the 39-amino-acid ACTH peptide \[[@SFW045C30]\]. Up until now, there has been no head-to-head comparison between these two forms of ACTH. On the basis of the current literature, patients with nephrotic syndrome responded to both forms of ACTH equally, and the adverse effect profiles were similar (Table [6](#SFW045TB6){ref-type="table"}).

There are no reported studies in the literature that directly compare ACTH with oral glucocorticoids in adults with glomerular diseases. As mentioned above, ACTH may be more advantageous than oral glucocorticoids since it may have direct protective effects on the podocyte \[[@SFW045C10]\]. Similarly, ACTH seems to have a better adverse effect profile compared with oral glucocorticoids. There was only 1 patient who reported bone loss among the 167 nephrotic patients treated with ACTH (0.5%). The low rate of bone loss in patients treated with ACTH may be due to the anabolic effect of ACTH, which has been shown to prevent bone loss \[[@SFW045C30], [@SFW045C31]\]. Therefore, ACTH could be more beneficial in patients who have osteoporosis and in whom the use of steroids is contraindicated \[[@SFW045C31]--[@SFW045C33]\]. The insulinogenic effect of the natural ACTH \[[@SFW045C8]\] may also decrease the incidence of glucose intolerance, considering only 2 of the 18 patients with diabetic nephropathy treated with natural ACTH required a reduction in their ACTH dose due to hyperglycemia \[[@SFW045C23], [@SFW045C30]\]. In this meta-analysis, ACTH was generally well tolerated. Edema was the most common adverse effect, which was managed with diuretics. Insomnia and mood swings were other common adverse effects. This could be due to the direct neurobiological effects of ACTH through melanocortin system activation \[[@SFW045C32]\]. Studies comparing the safety of ACTH with that of oral glucocorticoids are needed to better delineate the pros and cons of ACTH as a replacement for steroids when treating patients with glomerular diseases.

There are several limitations to our study. First, several factors decreased the quality of the evidence. About 40% of included citations were abstracts or letters to the editor, thus minimal details on patients\' baseline characteristics, treatment regimen and response criteria were provided. Most studies were small observational studies with limited controls and short-term follow-up. Second, there were statistical heterogeneities in the analysis of the incidence of adverse effects. The potential sources of these heterogeneities included differences in the types of glomerular diseases, baseline characteristics of patients and different formulations of ACTH. Third, the lack of consistent treatment effect was most likely due to heterogeneous baseline characteristics, specifically pretreatment, with other immunosuppressive therapies.

In conclusion, ACTH is a promising therapy for nephrotic syndrome in patients with MN. Overall it is well tolerated and has a more favorable adverse effect profile compared with corticosteroids. An RCT with extended follow-up is warranted to examine the efficacy and safety of ACTH therapy in nephrotic patients.
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###### Supplementary Data

[^1]: DN, diabetic nephropathy; FSGS, focal segmental glomerulosclerosis; IgA, IgA nephropathy; LN, lupus nephritis; MCD, minimal change disease; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis.

[^2]: \*Patients were also included in Hogan *et al*. \[[@SFW045C6]\].

[^3]: ACTH, adrenocorticotropic hormone; CR, complete response; GFR, glomerular filtration rate; IR, immunosuppression resistant (other than steroids); NA, data not available; naïve, never received immunosuppression; NR, no response; PR, partial response; SR, steroid resistant.

[^4]: Data presented as median and range;

[^5]: ^a^median (IQR);

[^6]: ^b^mean (SD);

[^7]: ^c^two patients received other immunosuppressive agents concomitant with ACTH.

[^8]: ACTH, adrenocorticotropic hormone; CR, complete response; IR, immunosuppression resistant (other than steroids); NA, data not available; naïve, never received immunosuppression; NR, no response; PR partial response; SR, steroid resistant.

[^9]: ^a^CR defined as urine protein excretion \<500 mg/day, PR defined as \>50% reduction of proteinuria and urine protein excretion \<3.5 g/day.

[^10]: ^b^CR defined as urine protein excretion \<200 mg/day, PR defined as \>50% reduction of proteinuria and urine protein excretion \<2 g/day.

[^11]: ^c^Response criteria were not provided.

[^12]: ^d^No reported treatment response, but significant reductions of urine protein excretion \<1 g/day were observed in most patients at 6 and 12 months.

[^13]: ACTH, adrenocorticotropic hormone; CR, complete response; GFR, glomerular filtration rate; IR, immunosuppression resistant (other than steroids); NA, data not available; naïve, never received immunosuppression; NR, no response; PR partial response; SD, steroid dependent; SR, steroid resistant.

[^14]: Data presented as median and range;

[^15]: ^a^one patient dropped out of the study (not included in the table);

[^16]: ^b^two patients received other immunosuppressive agents concomitant with ACTH.

[^17]: ACTH, adrenocorticotropic hormone; CR, complete response; IR, immunosuppression resistant (other than steroids); NA, data not available; NR, no response; PR partial response.

[^18]: ^a^Response criteria were not provided.

[^19]: ^b^CR defined as urine protein excretion \<500 mg/day; PR defined as \>50% reduction of proteinuria and urine protein excretion \<3.5 g/day.

[^20]: ^c^CR defined as urine protein excretion \<200 mg/day; PR defined as \>50% reduction of proteinuria and urine protein excretion \<2 g/day.

[^21]: ^d^All patients received other immunosuppressive agents concomitant with ACTH.

[^22]: ^e^Months after ACTH discontinuation.

[^23]: ACTH, adrenocorticotropic hormone.

[^24]: ACTH, adrenocorticotropic hormone; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN, membranous nephropathy; RAAS, renin--angiotensin--aldosterone system.

[^25]: Data are lacking to make any recommendations for lupus nephritis, MN and diabetic nephropathy.
